Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097500 on ClinicalTrials.gov · last registry update 2015-04-07

A small phase 3 — 69 participants, against a typical 424. The sponsor logged completion for December 2009. Primary outcome, as filed: Beta-cell Function After 52 Weeks of Therapy. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 69
Started: 2004-09
Primary completion: 2009-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Beta-cell Function After 52 Weeks of Therapy

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.